Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 16Unknown 5Recruiting 3Withdrawn 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 1

Interventions

Drug Therapy 107Cisplatin 97Radiotherapy 89Carboplatin 87Bevacizumab 79Oxaliplatin 74tislelizumab 68Capecitabine 67Cyclophosphamide 65Gemcitabine 64toripalimab 61Paclitaxel 57Specimen Handling 55pembrolizumab 54sintilimab 53Surgical Procedures, Operative 52anlotinib 49Magnetic Resonance Spectroscopy 49Fluorouracil 49Immune Checkpoint Inhibitors 43Blood Specimen Collection 42130-nm albumin-bound paclitaxel 42Standard of Care 39camrelizumab 36fludarabine 35lenvatinib 34Leucovorin 34venetoclax 30Radiosurgery 30Immunotherapy 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × OTHER × Embolization, Therapeutic × Clear all
NCT07612007 2026-06-01

HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization

Mayo Clinic

Phase 2 Not yet recruiting
80 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡